March E-news art

The FDA rejected an application to approve MDMA, also known as ecstasy. Now the agency treatment for PTSD. Next up among the psychedelics vying for an FDA approval: psilocybin for treatment resistant depression.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

A systemic review of corticosteroid studies finds that their anti-inflammatory effects can be beneficial in addressing peripheral injuries and as a adjuvant for treating the associated pain.

In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.

Boehringer Ingelheim said that it will submit a new drug application for nerandomilast based on the positive results.

The new program, which begins in January 2025, provides members of Prime Therapeutics support for navigating utilization management requirements and finding financial assistance.